Varma, Anika http://orcid.org/0000-0001-9533-7113
Weinstein, Jennifer
Seabury, Jamison
Rosero, Spencer
Dilek, Nuran
Heatwole, John
Engebrecht, Charlotte
Khosa, Shaweta
Chung, Kaitlin
Paker, Asif
Woo, Amy
Brooks, Gregory
Beals, Chan
Gandhi, Rohan
Heatwole, Chad
Funding for this research was provided by:
SwanBio Therapeutics
Autobahn Therapeutics
Article History
Received: 24 April 2023
Accepted: 3 March 2024
First Online: 19 March 2024
Declarations
:
: All study activities were approved by the University of Rochester Institutional Review Board, and all participants provided informed consent prior to taking part in study activities (interviews and/or cross-sectional study).
: Not applicable.
: AV does not have any competing interest to declare. JW does not have any competing interest to declare. JS does not have any competing interest to declare. SR does not have any competing interest to declare. CE does not have any competing interest to declare. ND does not have any competing interest to declare. JH does not have any competing interest to declare. SK does not have any competing interest to declare. KC does not have any competing interest to declare. AP, at the time this research was conducted, was an employee of SwanBio Therapeutics. AW, at the time this research was conducted, was an employee of Autobahn Therapeutics. GB is a current employee of Autobahn Therapeutics. CB, at the time this research was conducted, was an employee and stockholder of Autobahn Therapeutics. RG is a current employee of Autobahn Therapeutics. CH receives royalties for the use of multiple disease specific instruments. He has provided consultation to Biogen Idec, Ionis Pharmaceuticals, aTyr Pharma, AMO Pharma, Acceleron Pharma, Cytokinetics, Expansion Therapeutics, Harmony Biosciences, Regeneron Pharmaceuticals, Astellas Pharmaceuticals, AveXis, Recursion Pharmaceuticals, IRIS Medicine, Inc., Takeda Pharmaceutical Company, Scholar Rock, Avidity Biosciences, Novartis Pharmaceuticals Corporation, SwanBio Therapeutics, Neurocrine, and the Marigold Foundation. He receives grant support from the Department of Defense, Duchenne UK, Parent Project Muscular Dystrophy, Recursion Pharmaceuticals, SwanBio Therapeutics, Neurocrine Biosciences, the National Institute of Neurological Disorders and Stroke, the Muscular Dystrophy Association, the Friedreich’s Ataxia Research Alliance, Cure Spinal Muscular Atrophy, and the Amyotrophic Lateral Sclerosis Association. He is the director of the University of Rochester’s Center for Health + Technology.